Skip to content
NEW: CREATE AN AI-ASSISTED TENDER IN 2 MINUTES — TRY IT FREE
Back to search
FUTRUE – Fertigung

Healthcare group that develops and markets pharmaceuticals, probiotics and HealthTech technologies through specialized companies

FUTRUE Logo

FUTRUE GmbH

Gräfelfing (Am Haag 14, 82166)New on Amplifa

2008Founded
more than 20Group companies
more than 90Drug approvals
fewer than 180Employees per company

About FUTRUE

FUTRUE is an internationally active healthcare group founded in 2008 and headquartered in Gräfelfing near Munich. The corporate network comprises more than 20 companies with over 90 drug approvals; each company operates as a lean, highly specialized team with fewer than 180 employees. The group develops transformative drugs and technologies: the biopharmaceutical company VERTANICAL brought the cannabinoid-based pain drug VER-01 to approval, SYNformulas developed the probiotic medical device Kijimea Reizdarm, and PharmaSGP markets OTC pharmaceuticals and dietary supplements with brands such as Spalt, Formigran, Baldriparan and Restaxil. Further areas include brain-computer interfaces and neuromodulation devices (FUTRUE Neurosciences), microbiome research, clinical research services, and the international pharma media agency EMCM. The Managing Director of FUTRUE GmbH is founder Dr. Clemens Fischer.

Site
Gräfelfing
Processes
Development of pharmaceuticals and HealthTech technologies, Research and development services (clinical trials), Pharma media agency (print, TV, digital, e-detailing, DTC online campaigns), Development of probiotics/medical devices, OTC pharmaceuticals and dietary supplements, Development of brain-computer interfaces and neuromodulation devices, Microbiome research
Certificates
ISO 9001
Founded
2008
Industries
Pharmaceutical industry, Biotech, Consumer Health, HealthTech, Medical devices, Pharma media agency
  1. 01

    Research & Development

  2. 02

    Clinical Trials

  3. 03

    Approval & Regulatory Affairs

  4. 04

    Commercialization

  5. 05

    Pharma Media & Communications

Locations

Gräfelfing

DE

Headquarters

Inside the production

FUTRUE Healthcare Group
FUTRUE Healthcare Group

Industries

Pharmaceutical industryBiotechConsumer HealthHealthTechMedical devicesPharma media agency

Additional services

Development of pharmaceuticals and HealthTech technologiesResearch and development services (clinical trials)Pharma media agency (print, TV, digital, e-detailing, DTC online campaigns)Development of probiotics/medical devicesOTC pharmaceuticals and dietary supplementsDevelopment of brain-computer interfaces and neuromodulation devicesMicrobiome research

Reference customers

Publicly mentioned brands: Kijimea, Spalt, Formigran, Baldriparan, Restaxil, VER-01 (VERTANICAL)

Quality

No information on quality assurance certificates is available.

EvidenceGräfelfing
ISO 9001

History

  1. 2008

    Founding of FUTRUE by Dr. Clemens Fischer and Madlena Hohlefelder

  2. 2011

    Market launch of Kijimea Reizdarm, the first probiotic medical device for the treatment of irritable bowel syndrome

  3. 2026

    FDA Breakthrough status for VER-01 one month before approval; approval of VER-01 in July 2026

Personalised demo

Ready to see Amplifa Marketplace in action?

From a structured request to the right manufacturing partner: AI-assisted matching, verified suppliers and transparent metrics — in one place for industrial companies across the DACH region.

Request a demo